SMS Pharmaceuticals Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/qy3ufk5qwu4lr8a5gyl1b30y.pdf

Key Takeaways


Backward Integration & Margin Expansion

Potluri: "So actually, it is mostly the volume categories, like 80% major focus will be on the volume category because that's where the cost pressure is, on the volume ones, like some of the anti-diabetic segment is a critical one and anti-epileptic is one segment we're currently looking at."

Ibuprofen: Scale, Share & Stabilization


Inventory: Elevated but Manageable

Potluri: "The reason for the high inventory that we are currently maintaining... we have some high-volume products that we are currently moving in terms of volumes, like, for example, ibuprofen, which is high-volume product. And also, we have some old products where we are sitting on some inventory like HCQ... But definitely, in the next coming year, we have plans to reduce our inventory level. It will definitely come down."

Segment & Product Performance

SegmentTrendCommentary
Anti-inflammatory▲ StrongKey growth driver for the full year, supported by ibuprofen scale-up and market share gains.
ARV▲ StrongGood traction alongside anti-inflammatory as a primary revenue driver.
Anti-epileptic▲ Fastest growthGrew 106%, driven by strong demand and expanded market access.
Anti-diabetic▬ Modest growthGrew around 5% in value despite price softening; patents went off in Europe in 2025 but the company retained market share and volume.

Capex & Asset Efficiency

Potluri: "See, the target is one, to be honest with you. Right now, it is 0.67. If you look at our pharma industry, I think the average that is currently at this point of time, like from our peers, almost 20 companies like very close to us, is close to around 0.6 to 0.7 range, okay? So we are targeting to be around one, which is a very, very good number and very aggressive number."

Regulatory & Quality


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthTarget 20% revenue growth for FY26FY26
EBITDA margin expansionExpand EBITDA margins by 20%; anticipate around 20% margin growth on a conservative basisFY26
Backward integration margin impactMaterial margin improvement from backward integration beginsStarting Q2 FY26
Backward integration revenueRevenue from last year's backward integration capex starts factoring inFY26 (from Q2)
Ibuprofen volumeTarget close to 5,000 tons (vs 2,200 MT in FY25)FY26
HCQ inventory liquidationLiquidate INR40 crores of slow-moving HCQ inventory as customers anticipate launchNext 2-3 months
Inventory reductionReduce overall inventory level from current elevated positionFY26
New capex deploymentDeploy INR250 crores for capacity expansion in existing and new productsOver next 18 months
Asset turnoverReach asset turnover of 1 (from current 0.67)No date given

Key Metrics

MetricQ4 FY25
Revenue₹248 cr, +43% YoY
Full-year revenue₹783 cr, +10% YoY
Gross profit₹75 cr, +18% YoY
Gross margin30%, +444 bps YoY
Full-year gross margin33%, +330 bps YoY
EBITDA₹41 cr, +21% YoY
EBITDA margin16%
Full-year EBITDA margin18%
PAT₹20 cr, +18% YoY
PAT margin8%
Full-year PAT₹69 cr, +39% YoY
Anti-inflammatory segment revenue (FY25)₹148 cr, +22% YoY
ARV segment revenue (FY25)₹163 cr, +15% YoY
Anti-epileptic segment revenue (FY25)₹29 cr, +106% YoY
Anti-diabetic segment revenue (FY25)₹185 cr, +5% YoY
Antierectile dysfunction and other APIs revenue (FY25)+15% YoY
Inventory₹285 cr
Debt₹311 cr, with ₹20 cr annual interest cost
Slow-moving inventory (COVID-related)₹40 cr
Capex spent in FY25₹150 cr
Capex plan (next 18 months)₹250 cr
Investment in SMS Peptides Private Limited₹10 cr, in one or more tranches
Total asset turnover (FY25)0.67
Asset turnover target for new capex1
Capacity utilization75% to 80%
Ibuprofen volume (FY25)2,200 MT, vs 1,800 MT in FY24
Ibuprofen volume target (FY26)~5,000 tons
Ibuprofen regulated-market mix40% regulated, 60% domestic and ROW
FY26 revenue growth target20%
FY26 EBITDA margin target20%